Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.
No contrition, but Fortrend avoids big penalties in spat with Shaw & Partners pair
UAE developer acquires Roberts Co NSW with $20M cash boost, flags expansion
Coles sells Adelaide shopping centre for $75.2M
Judge slams ‘inadequate’ trial prep in case over failed $30M property deal
Allens-repped Rio Tinto in $75M deal for Yarraloola Project
Murphy takes 40% stake in Albergeldie Complex Infrastructure
A&O Shearman lures third Norton Rose Fulbright partner
Save (0) Please login to bookmark Close Username or Email Address Password Remember Me Recruiting its third partner from Norton Rose Fulbright in 18 months, law firm A&O Shearman has welcomed leading energy finance lawyer Lisa Koch to its Perth office. Koch was most recently head of Norton Rose Fulbright’s Sydney office, where she led…